Richard Pazdur, director of the FDA's Oncology Center of Excellence (via AACR)
April 18, 2022 11:34 AM EDT
FDA+

When OS is the 'ul­ti­mate safe­ty end­point': FDA lead­ers ques­tion sin­gle-arm tri­als amid scruti­ny of PI3K drugs for blood can­cer

Amber Tong

Is the saga of PI3K in­hibitors in hema­to­log­i­cal ma­lig­nan­cies spurring a re­think at the FDA about ac­cel­er­at­ed ap­provals and the reg­u­la­tion of blood can­cer drugs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

A VC-backed ge­net­ic test­ing start­up to 'con­sid­er' mak­ing an of­fer to buy 23andMe

Nu­ra Bio rais­es $68M for clin­i­cal tests of SARM1 in­hibitor to po­ten­tial­ly slow or pre­vent nerve de­gen­er­a­tion

Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets 

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times